» Articles » PMID: 11735337

Ablating Adenovirus Type 5 Fiber-CAR Binding and HI Loop Insertion of the SIGYPLP Peptide Generate an Endothelial Cell-selective Adenovirus

Overview
Journal Mol Ther
Publisher Cell Press
Date 2001 Dec 12
PMID 11735337
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Adenovirus type 5 (Ad) based vectors transduce vascular endothelial cells (EC) and have been widely used for vascular gene transfer. However, many cell types express the Ad receptor (cox-sackievirus adenovirus receptor; CAR), preventing selective EC infection and precluding clinical use. We previously isolated the human EC-binding peptides SIGYPLP and LSNFHSS by phage display and demonstrated by means of a bispecific antibody that SIGYPLP directs efficient, high-level, EC-selective Ad-mediated gene transfer. We now generate genetically modified Ad fiber proteins with selective EC tropism by engineering these peptides into the HI loop of the Ad fiber. SIGYPLP, but not LSNFHSS, enhanced EC selectivity, demonstrating maintenance of peptide-cell binding fidelity upon incorporation into virions. Combining fiber mutations that block CAR binding (detargeting) with SIGYPLP insertion (retargeting) generated a novel Ad vector, AdKO1SIG, in a single component system. AdKO1SIG demonstrated efficient and selective tropism for EC compared with control Ad vectors. This is the first demonstration of genetic incorporation of a novel, mammalian, cell-selective ligand that retains its targeting fidelity in the Ad fiber HI loop, in combination with point mutations that abolish fiber-CAR interaction. This study demonstrates the potential for improving the cell-selectivity and safety of adenoviral vectors.

Citing Articles

The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.

Sallard E, Zhang W, Aydin M, Schroer K, Ehrhardt A Viruses. 2023; 15(1).

PMID: 36680244 PMC: 9862123. DOI: 10.3390/v15010204.


Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.

Jt S, M H, Wam B, Ac B, Sa N J Mol Med (Berl). 2022; 100(6):875-901.

PMID: 35606652 PMC: 9126699. DOI: 10.1007/s00109-022-02208-0.


Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Bates E, Davies J, Vanova J, Nestic D, Meniel V, Koushyar S Mol Ther Oncolytics. 2022; 25:43-56.

PMID: 35399606 PMC: 8971729. DOI: 10.1016/j.omto.2022.03.007.


Vascular Endothelial Cells: Heterogeneity and Targeting Approaches.

Hennigs J, Matuszcak C, Trepel M, Korbelin J Cells. 2021; 10(10).

PMID: 34685692 PMC: 8534745. DOI: 10.3390/cells10102712.


Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.

Tessarollo N, Domingues A, Antunes F, Dos Santos da Luz J, Rodrigues O, Cerqueira O Cancers (Basel). 2021; 13(8).

PMID: 33919679 PMC: 8069790. DOI: 10.3390/cancers13081863.